Propanc Biopharma Outsources PK Assay Validation for Upcoming Trial
Event summary
- Propanc Biopharma has contracted FyoniBio GmbH, a Berlin-based CDO (formerly Glycotope), to establish and validate a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay.
- The assay will quantify Propanc’s lead asset, PRP (trypsinogen, chymotrypsinogen, trypsin, and chymotrypsin), in human serum during a Phase 1b First-In-Human (FIH) study.
- The FIH study is planned to commence in Q4 2026, targeting advanced cancer patients with solid tumors.
- The PK assay aims to measure PRP concentrations and assess safety/tolerability, with a sensitivity of at least 0.1µg/mL.
The big picture
Propanc’s decision to outsource PK assay development to FyoniBio is a common practice in early-stage biopharmaceutical development, particularly for companies lacking in-house analytical capabilities. This agreement underscores the increasing reliance on CDOs to accelerate drug development timelines, but also introduces potential dependencies and risks related to external expertise. The success of this partnership will be a key indicator of Propanc’s ability to advance its lead asset, PRP, through the clinic.
What we're watching
- Execution Risk
- Successful validation of the PK assay by FyoniBio is critical for the timely initiation of the Phase 1b trial, and any delays could impact Propanc’s development timeline.
- Clinical Trial Results
- The data generated from the PK assay will be crucial in determining the optimal PRP dosage and treatment duration in the FIH study, influencing the potential for future efficacy.
- CDO Dependence
- Propanc’s reliance on FyoniBio for this critical assay highlights the inherent risks associated with outsourcing key development activities to CDOs.
Related topics